



Willis-Knighton Cancer Center and IBA complete acceptance testing for Proteus[®]ONE

This achievement reaffirms IBA's world leading position in the delivery of highly targeted, safer cancer treatment solutions

Shreveport, Louisiana; Louvain-la-Neuve, Belgium; September 1st, 2014, IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that Willis-Knighton Cancer Center and IBA have completed acceptance testing of the first Proteus[®]ONE system ahead of schedule, opening the way to final commissioning and patient treatment with the most advanced compact Image Guided IMPT solution (Intensity Modulated Proton Therapy). The acceptance testing occurred less than 14 months after onsite delivery of the accelerator, demonstrating IBA's ability to deliver its solutions on schedule.

Proteus[®]ONE is IBA's single-room proton therapy system which is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including IBA's Intensity Modulated Proton Therapy (IMPT), and adapt Insight, the most advanced Image Guidance platform for Proton Therapy. IBA designed the Proteus[®]ONE system to allow more patients to access to proton therapy globally. Five Proteus[®]ONE units have already been sold by IBA: in Shreveport, Louisiana (USA), Nice (France), Taiwan (ROC) and two in Japan.

IBA anticipates that the international interest in Proteus[®]ONE will continue to grow thanks to the Marketing Authorization that has been received from the US FDA for its Compact Gantry Beam Line (CGBL: FDA 510(k) K132919) and for imaging platform adaPT Insight (FDA 510(k) K132847).

Yves Jongen, Founder and Chief Research Officer of IBA commented: "We are delighted to have completed the rigorous acceptance testing of Proteus[®]ONE at Willis-Knighton Cancer Center ahead of schedule. It is the talent and determination of our teams at IBA and the successful collaboration with Willis-Knighton's staff that made it possible to achieve this significant milestone. We very much look forward to the first patients being treated at the Willis-Knighton Cancer Centre later this year."

Lane R. Rosen, MD, Director of Radiation Oncology at the Willis-Knighton Cancer Centre, added: "We are very excited to have Intensity Modulated Proton Therapy become an available option for our patients. Both Willis-Knighton and IBA teams have been partnering at each step to ensure a smooth transition from installation to acceptance testing, leading to a possible first patient treatment in the very near future."

** Proteus[®]ONE is the brand name of a new configuration of the Proteus[®] 235.*

-ENDS-



Notes to Editors

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About the Willis-Knighton Cancer Center

Located in Shreveport Louisiana, the Willis-Knighton Cancer Center (WKCC) is the region's premier cancer treatment facility. WKCC provides a wide range of treatment options for cancer patients including radiation oncology, medical oncology and hematology, surgical oncology and gynecologic oncology. The Cancer Center provides diagnostic services such as PET, X-ray, CT and laboratory. It also offers support groups, counselling, nutritional and educational resources, and community education programs. More information can be found at www.wkhs.com/cancer.

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager Proton Therapy
+32 10 475 890
communication@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

Willis-Knighton Cancer Center

Marilyn Joiner
Director of Marketing & Public Relations
+1 318 212-8965
mjoiner@wkhs.com